Survey on the management of skin toxicity associated with EGFR inhibitors amongst French physicians. (Q43776983)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Survey on the management of skin toxicity associated with EGFR inhibitors amongst French physicians (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Thierry André

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Marc Ychou

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

L Peuvrel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

C Bachmeyer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Z Reguiai

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R J Bensadoun

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

O Bouché

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

B Dréno

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Regional expert groups PROCUR

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

1 reference

3 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

Journal of the European Academy of Dermatology and Venereology

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

419-429

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

Increased EGF receptors on human squamous carcinoma cell lines

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Skin toxicities of targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04421.X

10.1111/J.1468-3083.2011.04421.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211860%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference